CAP Revises Breast and GI Reporting
Updated protocols reflect changes in biomarker testing, staging, and accreditation
Clinical Scorecard: CAP Revises Breast and GI Reporting
At a Glance
Category Detail
Condition Breast and Gastrointestinal Stromal Tumors Key Mechanisms Updates to biomarker reporting and molecular testing protocols. Target Population Patients with breast cancer and gastrointestinal stromal tumors. Care Setting Pathology laboratories and oncology clinics.
Key Highlights
Updated scoring and reporting criteria for breast cancer biomarkers. New accreditation requirement for malignant phyllodes tumors. Expanded molecular testing options for gastrointestinal stromal tumors. Structured reporting for NTRK fusions in GISTs. Integration of updates with assay validation and quality control. Guideline-Based Recommendations
Diagnosis
Use updated protocols for consistent cancer diagnosis. Management
Incorporate biomarker findings into treatment planning. Monitoring & Follow-up
Ensure reports reflect the latest protocol elements. Risks
Potential need for changes in laboratory workflows and reporting templates. Patient & Prescribing Data
Patients with breast cancer and GISTs requiring biomarker testing.
Biomarkers help identify patients for endocrine or HER2-directed therapies.
Clinical Best Practices
Review and update laboratory information systems to align with new protocols. Ensure clear documentation of specimen and testing methods in molecular reports. Integrate updates with established quality control procedures. Related Resources & Content
